Evolving concepts in the management of chronic myeloid leukemia : recommendations from an expert panel on behalf of the European LeukemiaNet
Identifieur interne : 009F57 ( Main/Exploration ); précédent : 009F56; suivant : 009F58Evolving concepts in the management of chronic myeloid leukemia : recommendations from an expert panel on behalf of the European LeukemiaNet
Auteurs : Michele Baccarani [Italie, États-Unis, Allemagne, Suède, Royaume-Uni, Espagne, Suisse, France, Australie] ; Giuseppe Saglio ; John Goldman ; Andreas Hochhaus ; Bengt Simonsson ; Frederick Appelbaum ; Jane Apperley ; Francisco Cervantes ; Jorge Cortes ; Michael Deininger ; Alois Gratwohl ; Francois Guilhot ; Mary Horowitz ; Timothy Hughes ; Hagop Kantarjian ; Richard Larson ; Dietger Niederwieser ; Richard Silver ; Rudiger HehlmannSource :
- Blood [ 0006-4971 ] ; 2006.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Cellule souche, Homme.
English descriptors
- KwdEn :
Abstract
The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic myeloid leukemia (CML). Although experience is too limited to permit evidence-based evaluation of survival, the available data fully justify critical reassessment of CML management. The panel therefore reviewed treatment of CML since 1998. It confirmed the value of IM (400 mg/day) and of conventional allogeneic hematopoietic stem cell transplantation (alloHSCT). It recommended that the preferred initial treatment for most patients newly diagnosed in chronic phase should now be 400 mg IM daily. A dose increase of IM, alloHSCT, or investigational treatments were recommended in case of failure, and could be considered in case of suboptimal response. Failure was defined at 3 months (no hematologic response [HR]), 6 months (incomplete HR or no cytogenetic response [CgR]), 12 months (less than partial CgR [Philadelphia chromosome-positive (Ph+) > 35%]), 18 months (less than complete CgR), and in case of HR or CgR loss, or appearance of highly IM-resistant BCR-ABL mutations. Suboptimal response was defined at 3 months (incomplete HR), 6 months (less than partial CgR), 12 months (less than complete CgR), 18 months (less than major molecular response [MMoIR]), and, in case of MMoIR loss, other mutations or other chromosomal abnormalities. The importance of regular monitoring at experienced centers was highlighted.
Affiliations:
- Allemagne, Australie, Espagne, France, Italie, Royaume-Uni, Suisse, Suède, États-Unis
- Angleterre, Bade-Wurtemberg, District de Karlsruhe, Grand Londres, Nouvelle-Aquitaine, Oregon, Piémont, Poitou-Charentes
- Londres, Mannheim, Poitiers, Portland, Turin
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 004081
- to stream PascalFrancis, to step Curation: 002014
- to stream PascalFrancis, to step Checkpoint: 004055
- to stream Main, to step Merge: 00AA77
- to stream Main, to step Curation: 009F57
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Evolving concepts in the management of chronic myeloid leukemia : recommendations from an expert panel on behalf of the European LeukemiaNet</title><author><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Hematology/Oncology "L. and A. Seràgnoli" University of Bologna</s1><s3>ITA</s3></inist:fA14><country>Italie</country><wicri:noRegion>Department of Hematology/Oncology "L. and A. Seràgnoli" University of Bologna</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Clinical and Biological Sciences, University of Turin at Orbassano</s1><s2>Turin</s2><s3>ITA</s3></inist:fA14><country>Italie</country><placeName><settlement type="city">Turin</settlement><region type="région" nuts="2">Piémont</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>Bethesda, MD</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Faculty of Clinical Medicine Mannheim, University of Heidelberg</s1><s2>Mannheim</s2><s3>DEU</s3></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Mannheim</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Hematology, University Hospital</s1><s2>Uppsala</s2><s3>SWE</s3></inist:fA14><country>Suède</country><wicri:noRegion>Uppsala</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Clinical Research Division, Fred Hutchinson Cancer Research Center</s1><s2>Seattle, WA</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>Seattle, WA</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Department of Hematology, Hammersmith Hospital</s1><s2>London</s2><s3>GBR</s3></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Hematology Department, Hospital Clinic, Institut d'lnvestigacions Biomédiques August Pi i Sunyer (IDIBAPS), University of Barcelona</s1><s3>ESP</s3></inist:fA14><country>Espagne</country><wicri:noRegion>Hematology Department, Hospital Clinic, Institut d'lnvestigacions Biomédiques August Pi i Sunyer (IDIBAPS), University of Barcelona</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Leukemia, M. D. Anderson Cancer Center</s1><s2>Houston, TX</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>Houston, TX</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute</s1><s2>Portland</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Portland</settlement><region type="state">Oregon</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Hematology, University Hospital</s1><s2>Basel</s2><s3>CHE</s3></inist:fA14><country>Suisse</country><wicri:noRegion>Basel</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="12"><s1>Department of Oncology, Hematology and Cell Therapy, Medical Oncology, Equipe d'accueil (EA) 3805, and Clinical Research Centre, Centre Hospitalier et Universitaire (CHU) La Miletrie</s1><s2>Poitiers</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Poitou-Charentes</region><settlement type="city">Poitiers</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Centre for International Blood and Marrow Transplant Research</s1><s2>Medical College of Wisconsin, Milwaukee</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>Centre for International Blood and Marrow Transplant Research</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Institute of Medical and Veterinary Science</s1><s2>Adelaide, New South Wales</s2><s3>AUS</s3></inist:fA14><country>Australie</country><wicri:noRegion>Institute of Medical and Veterinary Science</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Department of Medicine and Cancer Research Center, University of Chicago</s1><s2>IL</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>IL</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="16"><s1>Department of Hematology and Oncology, University of Leipzig</s1><s3>DEU</s3></inist:fA14><country>Allemagne</country><wicri:noRegion>University of Leipzig</wicri:noRegion><wicri:noRegion>Department of Hematology and Oncology, University of Leipzig</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="17"><s1>New York Presbyterian-Weill Cornell Medical Center</s1><s2>New York, NY</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>New York Presbyterian-Weill Cornell Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Saglio, Giuseppe" sort="Saglio, Giuseppe" uniqKey="Saglio G" first="Giuseppe" last="Saglio">Giuseppe Saglio</name></author><author><name sortKey="Goldman, John" sort="Goldman, John" uniqKey="Goldman J" first="John" last="Goldman">John Goldman</name></author><author><name sortKey="Hochhaus, Andreas" sort="Hochhaus, Andreas" uniqKey="Hochhaus A" first="Andreas" last="Hochhaus">Andreas Hochhaus</name></author><author><name sortKey="Simonsson, Bengt" sort="Simonsson, Bengt" uniqKey="Simonsson B" first="Bengt" last="Simonsson">Bengt Simonsson</name></author><author><name sortKey="Appelbaum, Frederick" sort="Appelbaum, Frederick" uniqKey="Appelbaum F" first="Frederick" last="Appelbaum">Frederick Appelbaum</name></author><author><name sortKey="Apperley, Jane" sort="Apperley, Jane" uniqKey="Apperley J" first="Jane" last="Apperley">Jane Apperley</name></author><author><name sortKey="Cervantes, Francisco" sort="Cervantes, Francisco" uniqKey="Cervantes F" first="Francisco" last="Cervantes">Francisco Cervantes</name></author><author><name sortKey="Cortes, Jorge" sort="Cortes, Jorge" uniqKey="Cortes J" first="Jorge" last="Cortes">Jorge Cortes</name></author><author><name sortKey="Deininger, Michael" sort="Deininger, Michael" uniqKey="Deininger M" first="Michael" last="Deininger">Michael Deininger</name></author><author><name sortKey="Gratwohl, Alois" sort="Gratwohl, Alois" uniqKey="Gratwohl A" first="Alois" last="Gratwohl">Alois Gratwohl</name></author><author><name sortKey="Guilhot, Francois" sort="Guilhot, Francois" uniqKey="Guilhot F" first="Francois" last="Guilhot">Francois Guilhot</name></author><author><name sortKey="Horowitz, Mary" sort="Horowitz, Mary" uniqKey="Horowitz M" first="Mary" last="Horowitz">Mary Horowitz</name></author><author><name sortKey="Hughes, Timothy" sort="Hughes, Timothy" uniqKey="Hughes T" first="Timothy" last="Hughes">Timothy Hughes</name></author><author><name sortKey="Kantarjian, Hagop" sort="Kantarjian, Hagop" uniqKey="Kantarjian H" first="Hagop" last="Kantarjian">Hagop Kantarjian</name></author><author><name sortKey="Larson, Richard" sort="Larson, Richard" uniqKey="Larson R" first="Richard" last="Larson">Richard Larson</name></author><author><name sortKey="Niederwieser, Dietger" sort="Niederwieser, Dietger" uniqKey="Niederwieser D" first="Dietger" last="Niederwieser">Dietger Niederwieser</name></author><author><name sortKey="Silver, Richard" sort="Silver, Richard" uniqKey="Silver R" first="Richard" last="Silver">Richard Silver</name></author><author><name sortKey="Hehlmann, Rudiger" sort="Hehlmann, Rudiger" uniqKey="Hehlmann R" first="Rudiger" last="Hehlmann">Rudiger Hehlmann</name></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">06-0503292</idno><date when="2006">2006</date><idno type="stanalyst">PASCAL 06-0503292 LBEI</idno><idno type="RBID">Pascal:06-0503292</idno><idno type="wicri:Area/PascalFrancis/Corpus">004081</idno><idno type="wicri:Area/PascalFrancis/Curation">002014</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">004055</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">004055</idno><idno type="wicri:doubleKey">0006-4971:2006:Baccarani M:evolving:concepts:in</idno><idno type="wicri:Area/Main/Merge">00AA77</idno><idno type="wicri:Area/Main/Curation">009F57</idno><idno type="wicri:Area/Main/Exploration">009F57</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Evolving concepts in the management of chronic myeloid leukemia : recommendations from an expert panel on behalf of the European LeukemiaNet</title><author><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Hematology/Oncology "L. and A. Seràgnoli" University of Bologna</s1><s3>ITA</s3></inist:fA14><country>Italie</country><wicri:noRegion>Department of Hematology/Oncology "L. and A. Seràgnoli" University of Bologna</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Clinical and Biological Sciences, University of Turin at Orbassano</s1><s2>Turin</s2><s3>ITA</s3></inist:fA14><country>Italie</country><placeName><settlement type="city">Turin</settlement><region type="région" nuts="2">Piémont</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>Bethesda, MD</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Faculty of Clinical Medicine Mannheim, University of Heidelberg</s1><s2>Mannheim</s2><s3>DEU</s3></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Mannheim</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Hematology, University Hospital</s1><s2>Uppsala</s2><s3>SWE</s3></inist:fA14><country>Suède</country><wicri:noRegion>Uppsala</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Clinical Research Division, Fred Hutchinson Cancer Research Center</s1><s2>Seattle, WA</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>Seattle, WA</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Department of Hematology, Hammersmith Hospital</s1><s2>London</s2><s3>GBR</s3></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Hematology Department, Hospital Clinic, Institut d'lnvestigacions Biomédiques August Pi i Sunyer (IDIBAPS), University of Barcelona</s1><s3>ESP</s3></inist:fA14><country>Espagne</country><wicri:noRegion>Hematology Department, Hospital Clinic, Institut d'lnvestigacions Biomédiques August Pi i Sunyer (IDIBAPS), University of Barcelona</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Leukemia, M. D. Anderson Cancer Center</s1><s2>Houston, TX</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>Houston, TX</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute</s1><s2>Portland</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Portland</settlement><region type="state">Oregon</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Hematology, University Hospital</s1><s2>Basel</s2><s3>CHE</s3></inist:fA14><country>Suisse</country><wicri:noRegion>Basel</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="12"><s1>Department of Oncology, Hematology and Cell Therapy, Medical Oncology, Equipe d'accueil (EA) 3805, and Clinical Research Centre, Centre Hospitalier et Universitaire (CHU) La Miletrie</s1><s2>Poitiers</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Poitou-Charentes</region><settlement type="city">Poitiers</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Centre for International Blood and Marrow Transplant Research</s1><s2>Medical College of Wisconsin, Milwaukee</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>Centre for International Blood and Marrow Transplant Research</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Institute of Medical and Veterinary Science</s1><s2>Adelaide, New South Wales</s2><s3>AUS</s3></inist:fA14><country>Australie</country><wicri:noRegion>Institute of Medical and Veterinary Science</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Department of Medicine and Cancer Research Center, University of Chicago</s1><s2>IL</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>IL</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="16"><s1>Department of Hematology and Oncology, University of Leipzig</s1><s3>DEU</s3></inist:fA14><country>Allemagne</country><wicri:noRegion>University of Leipzig</wicri:noRegion><wicri:noRegion>Department of Hematology and Oncology, University of Leipzig</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="17"><s1>New York Presbyterian-Weill Cornell Medical Center</s1><s2>New York, NY</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><wicri:noRegion>New York Presbyterian-Weill Cornell Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Saglio, Giuseppe" sort="Saglio, Giuseppe" uniqKey="Saglio G" first="Giuseppe" last="Saglio">Giuseppe Saglio</name></author><author><name sortKey="Goldman, John" sort="Goldman, John" uniqKey="Goldman J" first="John" last="Goldman">John Goldman</name></author><author><name sortKey="Hochhaus, Andreas" sort="Hochhaus, Andreas" uniqKey="Hochhaus A" first="Andreas" last="Hochhaus">Andreas Hochhaus</name></author><author><name sortKey="Simonsson, Bengt" sort="Simonsson, Bengt" uniqKey="Simonsson B" first="Bengt" last="Simonsson">Bengt Simonsson</name></author><author><name sortKey="Appelbaum, Frederick" sort="Appelbaum, Frederick" uniqKey="Appelbaum F" first="Frederick" last="Appelbaum">Frederick Appelbaum</name></author><author><name sortKey="Apperley, Jane" sort="Apperley, Jane" uniqKey="Apperley J" first="Jane" last="Apperley">Jane Apperley</name></author><author><name sortKey="Cervantes, Francisco" sort="Cervantes, Francisco" uniqKey="Cervantes F" first="Francisco" last="Cervantes">Francisco Cervantes</name></author><author><name sortKey="Cortes, Jorge" sort="Cortes, Jorge" uniqKey="Cortes J" first="Jorge" last="Cortes">Jorge Cortes</name></author><author><name sortKey="Deininger, Michael" sort="Deininger, Michael" uniqKey="Deininger M" first="Michael" last="Deininger">Michael Deininger</name></author><author><name sortKey="Gratwohl, Alois" sort="Gratwohl, Alois" uniqKey="Gratwohl A" first="Alois" last="Gratwohl">Alois Gratwohl</name></author><author><name sortKey="Guilhot, Francois" sort="Guilhot, Francois" uniqKey="Guilhot F" first="Francois" last="Guilhot">Francois Guilhot</name></author><author><name sortKey="Horowitz, Mary" sort="Horowitz, Mary" uniqKey="Horowitz M" first="Mary" last="Horowitz">Mary Horowitz</name></author><author><name sortKey="Hughes, Timothy" sort="Hughes, Timothy" uniqKey="Hughes T" first="Timothy" last="Hughes">Timothy Hughes</name></author><author><name sortKey="Kantarjian, Hagop" sort="Kantarjian, Hagop" uniqKey="Kantarjian H" first="Hagop" last="Kantarjian">Hagop Kantarjian</name></author><author><name sortKey="Larson, Richard" sort="Larson, Richard" uniqKey="Larson R" first="Richard" last="Larson">Richard Larson</name></author><author><name sortKey="Niederwieser, Dietger" sort="Niederwieser, Dietger" uniqKey="Niederwieser D" first="Dietger" last="Niederwieser">Dietger Niederwieser</name></author><author><name sortKey="Silver, Richard" sort="Silver, Richard" uniqKey="Silver R" first="Richard" last="Silver">Richard Silver</name></author><author><name sortKey="Hehlmann, Rudiger" sort="Hehlmann, Rudiger" uniqKey="Hehlmann R" first="Rudiger" last="Hehlmann">Rudiger Hehlmann</name></author></analytic><series><title level="j" type="main">Blood</title><title level="j" type="abbreviated">Blood</title><idno type="ISSN">0006-4971</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Blood</title><title level="j" type="abbreviated">Blood</title><idno type="ISSN">0006-4971</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term><term>Chronic myelocytic leukemia</term><term>Clinical management</term><term>Cohort study</term><term>Europe</term><term>Hematopoietic cell</term><term>Homograft</term><term>Human</term><term>Imatinib</term><term>Posology</term><term>Stem cell</term><term>Therapeutic protocol</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Leucémie myéloïde</term><term>Traitement</term><term>Conduite à tenir</term><term>Imatinib</term><term>Anticancéreux</term><term>Posologie</term><term>Homogreffe</term><term>Cellule hématopoïétique</term><term>Cellule souche</term><term>Protocole thérapeutique</term><term>Homme</term><term>Europe</term><term>Etude cohorte</term><term>Leucémie myéloïde chronique</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Cellule souche</term><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic myeloid leukemia (CML). Although experience is too limited to permit evidence-based evaluation of survival, the available data fully justify critical reassessment of CML management. The panel therefore reviewed treatment of CML since 1998. It confirmed the value of IM (400 mg/day) and of conventional allogeneic hematopoietic stem cell transplantation (alloHSCT). It recommended that the preferred initial treatment for most patients newly diagnosed in chronic phase should now be 400 mg IM daily. A dose increase of IM, alloHSCT, or investigational treatments were recommended in case of failure, and could be considered in case of suboptimal response. Failure was defined at 3 months (no hematologic response [HR]), 6 months (incomplete HR or no cytogenetic response [CgR]), 12 months (less than partial CgR [Philadelphia chromosome-positive (Ph+) > 35%]), 18 months (less than complete CgR), and in case of HR or CgR loss, or appearance of highly IM-resistant BCR-ABL mutations. Suboptimal response was defined at 3 months (incomplete HR), 6 months (less than partial CgR), 12 months (less than complete CgR), 18 months (less than major molecular response [MMoIR]), and, in case of MMoIR loss, other mutations or other chromosomal abnormalities. The importance of regular monitoring at experienced centers was highlighted.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Espagne</li><li>France</li><li>Italie</li><li>Royaume-Uni</li><li>Suisse</li><li>Suède</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Bade-Wurtemberg</li><li>District de Karlsruhe</li><li>Grand Londres</li><li>Nouvelle-Aquitaine</li><li>Oregon</li><li>Piémont</li><li>Poitou-Charentes</li></region><settlement><li>Londres</li><li>Mannheim</li><li>Poitiers</li><li>Portland</li><li>Turin</li></settlement></list><tree><noCountry><name sortKey="Appelbaum, Frederick" sort="Appelbaum, Frederick" uniqKey="Appelbaum F" first="Frederick" last="Appelbaum">Frederick Appelbaum</name><name sortKey="Apperley, Jane" sort="Apperley, Jane" uniqKey="Apperley J" first="Jane" last="Apperley">Jane Apperley</name><name sortKey="Cervantes, Francisco" sort="Cervantes, Francisco" uniqKey="Cervantes F" first="Francisco" last="Cervantes">Francisco Cervantes</name><name sortKey="Cortes, Jorge" sort="Cortes, Jorge" uniqKey="Cortes J" first="Jorge" last="Cortes">Jorge Cortes</name><name sortKey="Deininger, Michael" sort="Deininger, Michael" uniqKey="Deininger M" first="Michael" last="Deininger">Michael Deininger</name><name sortKey="Goldman, John" sort="Goldman, John" uniqKey="Goldman J" first="John" last="Goldman">John Goldman</name><name sortKey="Gratwohl, Alois" sort="Gratwohl, Alois" uniqKey="Gratwohl A" first="Alois" last="Gratwohl">Alois Gratwohl</name><name sortKey="Guilhot, Francois" sort="Guilhot, Francois" uniqKey="Guilhot F" first="Francois" last="Guilhot">Francois Guilhot</name><name sortKey="Hehlmann, Rudiger" sort="Hehlmann, Rudiger" uniqKey="Hehlmann R" first="Rudiger" last="Hehlmann">Rudiger Hehlmann</name><name sortKey="Hochhaus, Andreas" sort="Hochhaus, Andreas" uniqKey="Hochhaus A" first="Andreas" last="Hochhaus">Andreas Hochhaus</name><name sortKey="Horowitz, Mary" sort="Horowitz, Mary" uniqKey="Horowitz M" first="Mary" last="Horowitz">Mary Horowitz</name><name sortKey="Hughes, Timothy" sort="Hughes, Timothy" uniqKey="Hughes T" first="Timothy" last="Hughes">Timothy Hughes</name><name sortKey="Kantarjian, Hagop" sort="Kantarjian, Hagop" uniqKey="Kantarjian H" first="Hagop" last="Kantarjian">Hagop Kantarjian</name><name sortKey="Larson, Richard" sort="Larson, Richard" uniqKey="Larson R" first="Richard" last="Larson">Richard Larson</name><name sortKey="Niederwieser, Dietger" sort="Niederwieser, Dietger" uniqKey="Niederwieser D" first="Dietger" last="Niederwieser">Dietger Niederwieser</name><name sortKey="Saglio, Giuseppe" sort="Saglio, Giuseppe" uniqKey="Saglio G" first="Giuseppe" last="Saglio">Giuseppe Saglio</name><name sortKey="Silver, Richard" sort="Silver, Richard" uniqKey="Silver R" first="Richard" last="Silver">Richard Silver</name><name sortKey="Simonsson, Bengt" sort="Simonsson, Bengt" uniqKey="Simonsson B" first="Bengt" last="Simonsson">Bengt Simonsson</name></noCountry><country name="Italie"><noRegion><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name></noRegion><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name></country><country name="États-Unis"><noRegion><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name></noRegion><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name></country><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name></region><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name></country><country name="Suède"><noRegion><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name></noRegion></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name></region></country><country name="Espagne"><noRegion><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name></noRegion></country><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name></region></country><country name="Australie"><noRegion><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009F57 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 009F57 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:06-0503292
|texte= Evolving concepts in the management of chronic myeloid leukemia : recommendations from an expert panel on behalf of the European LeukemiaNet
}}
| This area was generated with Dilib version V0.6.33. |  |